ever, these are problems which are easily overcome. Many reliable methods have been described for the estimation of both plasma ammonia and glutamine (Levin, 1971) . Everyone concerned with metabolic screening should be aware of the precautions and techniques needed to be able to measure accurately plasma levels of these substances.
It will be apparent that only in certain urea cycle defects does the provisional diagnosis depend on the measurement of ammonia and glutamine. There is no problem in diagnosing ASA synthetase deficiency because of the large amounts of citrulline which will be present in blood and urine. Similarly there will be no problem in diagnosing ASA lyase deficiency, where large amounts of ASA and also of citrulline will be found, nor of diagnosing arginase deficiency, where large amounts of arginine will be present. The main problem is the diagnosis of OTC deficiency and CPS deficiency, where there is no build-up of any characteristic amino-acid.
It should be stressed that, especially in the case of OTC deficiency, prompt diagnosis and treatment may be of tremendous value to the patient. All the available evidence indicates that OTC deficiency is an X-linked dominant disease. Males are severely affected, but the expression in females can vary from the very severe to the very mild. Because of the nature of the inheritance it is probably a relatively common disease but is escaping detection for the reasons discussed earlier. Subjects with the major problems resulting from failures of diagnosis are mildly affected females. There are many examples of patients whose condition has deteriorated irreversibly during the months and years of investigation before a correct diagnosis has been made. It seems that even in mildly affected cases an infection or a large meal can precipitate a crisis, with possibly fatal consequences. Obviously the extent of the crisis is likely to be more severe if the patient is undiagnosed and not being maintained on a controlled diet. In contrast to these cases are patients brought into hospital in coma who have made a full recovery because of prompt diagnosis and immediate and continued treatment by low protein intake. Therefore, for all urea cycle defects, and particularly for mildly affected females with OTC deficiency, early diagnosis is very important.
A detailed look at the clinical features can itself
The function of the urea cycle is to remove excess ammonia from the body, ammonia being the end product of protein metabolism. Five enzymes are involved, carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinate (ASA) synthetase, ASA lyase, and arginase. Inherited defects of all of these enzymes are known, though in the case of CPS deficiency and arginase deficiency very few cases have so far been described.
These diseases are all related, since they are all defects along the pathway of ammonia detoxification, and all result in a build-up of ammonia levels in body tissues and fluids. Thus they have certain clinical and biochemical features in common. The clinical features are those of ammonia intoxication coupled with protein intolerance. In general symptoms become worse after high protein intake and improve after treatment by low protein intake.
The characteristic biochemical feature common to all these disorders is that plasma and urine ammonia levels are raised. Levels of glutamine, which has close metabolic links with ammonia, are also raised. Glutamic acid levels, which might similarly be expected to be high, are in fact normal, but alanine, which is linked to glutamic acid by transamination reactions and which may be the main carrier of nitrogen to the liver from extra-hepatic tissues (Felig, 1973) , is occasionally found in increased amounts. These are the only biochemical abnormalities common to all urea cycle defects. Blood urea levels may be within normal limits, so determination of blood urea is of limited help in diagnosis.
Here then is the main problem in diagnosing these conditions, for both ammonia and glutamine are difficult to measure accurately. Plasma glutamine decays on storage, even at -20 DC, ammonia being one of the products (Dickinson et al., 1965; Palmer et al., 1974a) .
As there is very much more glutamine than ammonia normally present in plasma, a slight decay of the plasma glutamine can greatly affect the measured plasma ammonia level. This, plus the dangers of contamination, makes the accurate determination of plasma ammonia difficult unless special precautions are taken. There are also problems in estimating glutamine levels by ion exchange chromatography, since glutamine decays on the columns at the high temperatures often used. How-136
indicate the likelihood or otherwise of the diagnosis. The typical mildly affected female will be of the type likely to be investigated for a possible neurological disorder. Headaches and vomiting will usually be the first signs, followed by convulsions leading to coma and hepatomegaly. If the vomiting, headaches, and general drowsiness appear more severe after ingestion of protein, a urea cycle defect is a possibility. Another important pointer is evidence that the patient dislikes protein; if there is no correlation between severity of symptoms and protein intake---e.g., no improvement when being fed only intravenous glucose-a urea cycle defect is unlikely, except in terminal cases.
Below are a series of tests which should ensure the quick diagnosis of a urea cycle defect once the possibility has been suggested by clinical features or other evidence. These start with simple tests which should be able to be performed in most hospital laboratories and lead on to more specialised ones which inevitably have to be done in centres specialising in this work. This approach is useful for two reasons. The simple tests allow a provisional diagnosis to be made quickly and locally, so treatment can be started while more detailed confirmatory tests are being done elsewhere. Moreover, if the simple tests give normal results there is no need to proceed further.
The simplest and quickest chemical test is the estimation of the ammonia in urine and to express this as a ratio to creatinine or urea. The measurement of urine ammonia is easier than measurement of plasma ammonia; however, the estimation should be done on a freshly collected specimen. Since in urea cycle defects urine ammonia levels are increased and urine urea levels are decreased, there is a good distinction between patients with urea cycle defects and controls. A patient with a urine ammonia-NI urea-N ratio in excess of 0.15 or a urine ammonia-N exceeding 1.5 gig creatinine is likely to have a urea cycle defect. Treated cases usually have lower ratios than untreated ones, but all are usually above normal limits. Since ammonia excretion by the kidney depends on pH, this should be considered in the interpretation of results. Although a series of patients with various types of acidosis were all found to have the above ratios within the normal range, this does vary with urine pH (e.g., the upper limit of normal for ammonia-creatinine is 2.0 at pH 5.0, 1.0 at pH 6.0, and about 0.5 at pH 7.5). Therefore, particularly in borderline cases (e.g., treated or very mildly affected) consideration of urine pH may facilitate diagnosis. The next step is to chromatograph the urine (paper or thin layer) and to examine the chromatogram under ultraviolet light (short wavelength). Pyrimidine metabolites, orotic acid, uridine, Diagnosis 0/ urea cycle disorders 137 and uracil levels, which show up as dark bands under ultraviolet light, are alternative products of carbamyl phosphate metabolism, and are present in increased amounts in the urine in all urea cycle defects except CPS deficiency, where there is restricted synthesis of carbamyl phosphate Oberholzer and Palmer, 1976) . These findings are in spite of the fact that there are two CPS enzymes within the body, one apparently geared to the urea cycle and one to the metabolism of pyrimidines. It is worth pointing out that, since amino-acid patterns and ammonia levels are similar in OTC and CPS deficiency, the investigation of pyrimidines may therefore be the only way of distinguishing between these two conditions short of performing a liver enzyme assay.
After the chromatogram is viewed in ultraviolet light it is stained with ninhydrin to investigate aminoacid levels. All urea cycle defects show increased glutamine and sometimes alanine levels; some have other characteristic amino-acid abnormalities.
On the basis of these tests it should be reasonably certain whether the case under investigation has a urea cycle defect or not.
Pyrimidines can be investigated in more detail by making a concentrate of the urine and removing amino-acids by the use of ion exchange columns. Chromatography, paper or thin layer, can be performed on the concentrate, the ultraviolet absorbing compounds will now be more prominent. If positive identification is required, the spots can be eluted and their spectra determined . Alternatively the chromatogram can be stained with Ehrlich's reagent to detect those pyrimidine metabolites not absorbing in ultraviolet light. Of these N-carbamyl aspartate and N-carbamyl fJ-alanine react with Ehrlich's reagent. Urine levels of Ncarbamy fJ-alanine in excess of 10 mg/g creatinine indicate a urea cycle defect other than CPS deficiency (Oberholzer and Palmer, 1976) .
Plasma ammonia levels should be determined, taking steps to avoid production of ammonia on storage and to avoid contamination at all stages of collection and analysis. Ideally analyses should be performed as quickly as possible after sample collection.
Plasma amino-acid analysis may be performed, either qualitatively by thin layer chromatography or quantitatively by ion exchange chromatography. Plasma glutamine gives a remarkably consistent indicator of the presence of the urea cycle defect. Even in treated cases, when the plasma ammonia levels tend to fall near or even within normal limits, fasting plasma glutamine levels are still high (Palmer et al., 1974b) . However, raised glutamine levels are found in conditions other than urea cycle defects, e.g., in patients being treated with certain anticonvulsant drugs.
Confirmation of a urea cycle defect is by enzyme assay. Some enzymes, e.g., ASA lyase, may be determined in red blood cells or skin cells, but others such as GTC cannot. However, GTC defects have been indicated by measuring ratios of GTC to other enzymes in serum (Pollit et al., 1977) . These assays of easily accessible material are guides to diagnosis. If a definitive diagnosis is required, enzyme assay of a liver biopsy specimen must be performed.
In conclusion, though certain urea cycle defects may be more difficult to diagnose than others, the sequence of tests described should ensure the rapid diagnosis of any urea cycle defect in a patient where this is suspected.
